09:39 AM EDT, 10/22/2024 (MT Newswires) -- MacroGenics ( MGNX ) and TerSera Therapeutics said Tuesday they have signed an agreement under which TerSera will buy global rights to breast cancer drug Margenza.

Under the deal, TerSera will pay MacroGenics ( MGNX ) $40 million at closing, the companies said, adding MacroGenics ( MGNX ) may get sales milestone payments of up to $35 million.

The deal is expected to close in Q4.

Price: 3.88, Change: +0.02, Percent Change: +0.39